Novo Nordisk A/S Common Stock (NY:NVO)

37.05 -0.27 (-0.74%)

Delayed Quote Updated: 9:49 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment ↗

September 16, 2025

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

Via Benzinga

3 Undervalued Healthcare Stocks to Buy Now While They're Cheap ↗

September 16, 2025

In an otherwise hot stock market, healthcare stocks are underperforming.

Via The Motley Fool

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO

September 16, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO

September 16, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report ↗

September 12, 2025

Via Stocktwits

Here Is My Top Stock Pick Among the Weight Loss Industry Leaders ↗

September 16, 2025

The weight loss drug market may reach $95 billion within five years.

Via The Motley Fool

What's Going On With Novo Nordisk Shares Monday? ↗

September 15, 2025

Novo Nordisk shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

Via Benzinga

Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact ↗

September 15, 2025

EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients.

Via Benzinga

Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition

September 15, 2025

Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance....

Via MarketMinute

Topics Economy Intellectual Property

Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook

September 15, 2025

Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

Why Novo Nordisk Stock Popped Today ↗

September 15, 2025

A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.

Via The Motley Fool

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO

September 15, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO

September 15, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm

September 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

September 15, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks ↗

September 13, 2025

FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA...

Via Benzinga

NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

September 12, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

September 12, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment

September 12, 2025

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

How Do Investors Really Feel About Novo Nordisk? ↗

September 12, 2025

Via Benzinga

Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO

September 11, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback ↗

September 11, 2025

One of them is already a leader in the market for weight management drugs, and the other could join this field.

Via The Motley Fool

Topics ETFs

ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

September 11, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Novo Nordisk’s “Employee Diet” Trims Workforce By 9,000

September 11, 2025

Via AB Newswire

Topics Economy Workforce

Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO

September 11, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO

September 11, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm

September 11, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades ↗

September 11, 2025

A decade from now, you could regret ignoring these no-brainer stock picks.

Via The Motley Fool

Topics Intellectual Property

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.